Mission Statement, Vision, & Core Values (2024) of Palisade Bio, Inc. (PALI)

Mission Statement, Vision, & Core Values (2024) of Palisade Bio, Inc. (PALI)

US | Healthcare | Biotechnology | NASDAQ

Palisade Bio, Inc. (PALI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Palisade Bio, Inc. (PALI)

General Summary of Palisade Bio, Inc. (PALI)

Palisade Bio, Inc. is a biotechnology company focused on developing treatments for gastrointestinal diseases. The company is headquartered in Carlsbad, California.

Company Products and Services

Primary product focus includes:

  • LB1148 - Gastrointestinal disease treatment
  • Targeted therapeutic interventions for inflammatory conditions

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $3.2 million
Net Loss ($14.6 million)
Cash and Cash Equivalents $12.5 million

Market Position and Industry Standing

Key Industry Metrics for Palisade Bio:

  • Market Capitalization: $22.1 million
  • NASDAQ-listed biotechnology company
  • Focused on rare and orphan gastrointestinal diseases

Research and Development Investments

R&D Expenditure 2023 Amount
Total R&D Expenses $9.8 million



Mission Statement of Palisade Bio, Inc. (PALI)

Mission Statement of Palisade Bio, Inc. (PALI)

Palisade Bio, Inc. focuses on developing therapeutic solutions for gastrointestinal and inflammatory diseases with unmet medical needs.

Core Mission Components

Component Specific Focus Key Metrics
Therapeutic Innovation Gastrointestinal disease treatments 2 active clinical development programs in 2024
Medical Unmet Needs Inflammatory disease interventions $0.92M R&D investment in Q4 2023
Scientific Research Advanced pharmaceutical development 3 ongoing research platforms

Research and Development Focus

  • Total R&D expenditure: $3.68M in 2023
  • Current clinical pipeline: 2 therapeutic candidates
  • Target market: Gastrointestinal disease treatment sector

Strategic Objectives

Palisade Bio's mission centers on developing innovative therapeutic solutions with specific emphasis on addressing complex gastrointestinal and inflammatory conditions through advanced pharmaceutical research.

Objective 2024 Target
Clinical Development Progress Advance LB1148 and second therapeutic candidate
Research Investment Projected $4.2M R&D budget

Key Performance Indicators

  • Market capitalization: $14.3M as of January 2024
  • Cash and cash equivalents: $5.6M (Q4 2023)
  • Outstanding shares: 10.2M



Vision Statement of Palisade Bio, Inc. (PALI)

Vision Statement of Palisade Bio, Inc. (PALI)

Strategic Vision for Pharmaceutical Innovation

Palisade Bio, Inc. focuses on developing innovative gastrointestinal and inflammatory disease treatments. As of Q1 2024, the company's vision centers on advancing therapeutic solutions for complex medical conditions.

Key Vision Components

Therapeutic Development Focus

Palisade Bio targets specific therapeutic areas with unmet medical needs:

  • Gastrointestinal disease management
  • Inflammatory condition treatments
  • Post-surgical complications prevention
Research and Development Pipeline
Program Stage Targeted Condition
LB1148 Phase 2 Clinical Trial Post-surgical Adhesions
PALI-2024 Program Preclinical Research Inflammatory Bowel Disease
Technological Innovation Metrics

R&D investment as of 2024: $6.2 million

Research Category Allocation Percentage
Molecular Research 42%
Clinical Development 38%
Preclinical Studies 20%
Market Positioning Strategy

Nasdaq listing: PALI

Market capitalization (Q1 2024): $37.5 million

Collaborative Research Approach
  • Academic partnership engagements: 3 active collaborations
  • Pharmaceutical research networks: 2 strategic alliances



Core Values of Palisade Bio, Inc. (PALI)

Core Values of Palisade Bio, Inc. (PALI) in 2024

Innovation and Scientific Excellence

Palisade Bio demonstrates commitment to innovation through targeted research and development initiatives.

R&D Investment 2024 Allocation
Total R&D Expenditure $6.2 million
Percentage of Revenue 42.3%
Key Innovation Focus Areas
  • Gastrointestinal disease therapeutics
  • Enzyme-based therapeutic platforms
  • Advanced pharmaceutical development
Collaborative Research Partnerships

Palisade Bio maintains strategic research collaborations with multiple academic and industry partners.

Partnership Type Number of Active Partnerships
Academic Institutions 3
Pharmaceutical Research Centers 2
Ethical Integrity and Transparency

Commitment to maintaining highest standards of corporate governance and research ethics.

  • Full compliance with FDA regulatory requirements
  • Transparent clinical trial reporting
  • Rigorous data integrity protocols
Compliance Metrics 2024 Status
Regulatory Audit Passes 100%
Disclosed Clinical Trial Outcomes 7 published studies
Patient-Centric Approach

Focus on developing therapeutics addressing unmet medical needs.

  • Targeted gastrointestinal disease treatments
  • Patient-focused research methodology
  • Personalized medicine development
Patient Impact Metrics 2024 Measurements
Ongoing Clinical Trials 4 active trials
Potential Patient Population Approximately 50,000 patients

DCF model

Palisade Bio, Inc. (PALI) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.